247 results
8-K
EX-99.1
ARWR
Arrowhead Pharmaceuticals Inc.
9 May 24
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
4:11pm
, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other … ; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements
S-8
EX-4.6
ARWR
Arrowhead Pharmaceuticals Inc.
28 Feb 24
Registration of securities for employees
5:25pm
, or (ii) is not reasonably likely to significantly diminish the benefits provided under such Award, or that any such diminishment has been adequately
8-K
EX-99.1
vkps8shu1z0j4it3exdm
6 Feb 24
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
4:07pm
8-K
EX-1.1
i7xp ojcndppgf
4 Jan 24
Entry into a Material Definitive Agreement
5:27pm
424B5
d3yd2crjj b8
4 Jan 24
Prospectus supplement for primary offering
5:01pm
8-K
EX-99.1
4hluf c160oro
29 Nov 23
Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results
4:10pm
8-K
EX-99.1
p608xaqqr4h
7 Aug 23
Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
4:10pm
8-K
EX-99.1
llzesxl4ltfow4ka
2 May 23
Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
4:09pm
8-K
EX-1.1
rz4s2xv8lzgisob
8 Dec 22
Entry into a Material Definitive Agreement
4:46pm
S-3ASR
EX-4.2
u4jwndag
2 Dec 22
Automatic shelf registration
9:23pm
S-3ASR
3dl4 1qphila8wm
2 Dec 22
Automatic shelf registration
9:23pm
S-3ASR
EX-1.2
kg39ott
2 Dec 22
Automatic shelf registration
9:23pm